The unit of South Korea’s Samsung Group, along with partner and minority shareholder Biogen (BIIB), filed suit in Britain on March 24 against AbbVie (ABBV), maker of rheumatoid arthritis drug Humira, which generated sales of $14 billion last year.

It is the company’s first suit against a drug originator.

Interest in biosimilars—lower-cost copies of complex biotech drugs—has soared in recent years as copies of some of the world’s best-selling prescription medicines have hit the market.

Unlike generic versions of simple chemical medicines, biotech drugs are made from living cells, so it is impossible to manufacture exact copies.

The IMS Institute for Healthcare Informatics says biosimilars could save healthcare systems in the United States and Europe’s top five markets as much as €98 billion ($111 billion) by 2020.

The South Korean conglomerate is hoping for big things from the unit—including a revenue target of 1 trillion won ($872 million) by 2020—amid sagging profits at its electronics business, Samsung Electronics (SSNLF), the world’s biggest maker of smartphones and televisions.

Success in the endeavor is seen as key for de facto Samsung Group leader Jay Y. Lee, 47, to prove himself as steward of the family-run smartphones-to-insurance empire. His father, group patriarch Lee Kun-hee, has been hospitalized since a 2014 heart attack.

Pushback

The composition patent for Humira loses its exclusivity in the United States in December 2016, and in Europe in October 2018, but Illinois-based AbbVie, which earned 61% of its 2015 net revenue from Humira, has been filing new patents in a bid to push back sales of biosimilars.

In addition to Samsung Bioepis and Biogen, more than a dozen firms have challenged AbbVie’s strategy through patent authorities or the courts.

“We believe that AbbVie has been attempting to obstruct market entry of competing products by applying for a large number of overlapping patents around Humira, which could affect patient access to affordable medication,” Samsung Bioepis told Reuters.

“We believe competition should take place in the market, and not through such misuse of the patent system,” it added.

AbbVie told Reuters it was aware of the lawsuit filed by Samsung Bioepis and Biogen.

“As we have said, we intend to defend our intellectual property,” it said.

Samsung Bioepis, which brought its first drug to market late last year, has a pipeline of 13 biosimilars, versions of existing drugs with similar efficacy at much lower prices, and is initially focusing on six of them to get out in front of the market.

The Samsung Group has a track record of moving fast. Late to enter the smartphone market, Samsung Electronics quickly rose to become the industry leader. The group is also one of the world’s most active patent filers and has over the years tried to move beyond its image as a “fast follower.”

“The first drug to hit the market takes the most market share, so this is the right strategy to go with,” said Kang Yang-ku, analyst at HMC Investment & Securities.

There are potentially rich pickings for early movers; more than 10 blockbuster biological drugs with combined yearly sales of $60 billion are on track to see their U.S. and European patents expire over the next four years, according to Allied Market Research.

Biosimilars are a source of consternation for investors in firms such as AbbVie, however, as the cheaper copies threaten to undercut profits for the original drug makers.

In December Bioepis began selling a biosimilar of Amgen’s arthritis drug Enbrel in South Korea, and the drug has since launched in some European markets including Germany and Britain early this year. The European Medicines Agency on Friday also recommended the Bioepis copy of another blockbuster drug Remicade for approval in Europe.

Samsung Bioepis is 91%-owned by Samsung Biologics, which manufactures biological drugs and is in turn mostly owned by Samsung C&T Corp and Samsung Electronics.